Policy and Advocacy Update - IN.gov

Policy and Advocacy Update - IN.gov

ABUSE DETERRENT OPIOIDS: THE PROMISE AND THE PERILS Bob Twillman, Ph.D., FAPM Executive Director American Academy of Pain Management Two Major Public Health Problems Prescription opioid abuse: 12.5 million non-medical users per year $70-120 billion cost per year 16,000 overdose deaths per year Chronic pain: >100 million with chronic pain, ~39 million with nearly

daily chronic pain, ~25 million with daily chronic pain, ~10 million disabled $560-635 billion cost per year Suicide risk doubled 39,500 suicide deaths in 2011 ~26,000 were people with chronic pain More Commonalities than Differences Prescription drug abuse and chronic pain are more alike than different: Both are highly prevalent Both are very costly, economically

Both highly stigmatized, and patients are blamed Both involve tremendous suffering Both are poorly understood by the medical profession Both are under-resourced vis--vis treatment Both are very complex problems, with many moving parts Not A Zero-Sum Game Often, it feels like any attempt to rein in prescription drug abuse must, of necessity, rein in prescribing, even for people with pain Similarly, it often seems as though any effort to improve pain management must involve increased prescribing,

which could, in turn, lead to increased prescription drug abuse I believe this mis-states the case, and that it is possible to address both problems with adversely affecting either A Thought For every complex problem, there is a solution that is neat, simple, and wrongH.L. Mencken I believe that implementing overly simplistic policy solutions for these two very complex problems leads to the zero-sum game that we so often perceive Perhaps the solutions we should be seeking are as complex as the problems we are trying to solve

Good Pain Management Helps Prevent Prescription Drug Abuse Appropriate treatment for chronic pain is multimodal and involves multiple providers This kind of treatment focuses primarily on improving function, recognizing that this can happen even with minimal (or no) improvement in pain intensity Use of multiple types of treatment should reduce reliance on opioid analgesics as the primary (and sometimes only) means of treating pain Multiple barriers exist to providing this type of care for chronic pain

Federal and State Pain Management Policy Issues Abuse-Deterrent Opioids Mandatory CME/CE Availability of substance abuse treatment Reimbursement for services other than prescribing and procedures Prescription Monitoring Programs

Prior Authorization/Step Therapy/Specialty Tier Good Samaritan/Naloxone Distribution and Administration Prescribing Guidelines Pain Clinic Regulation How Do People Die of Overdoses Involving Opioids? Accidental, during self-medication or recreational use Therapeutic misadventure (one or more of the following) Dose too high Comorbid medical conditions Combination with other prescribed medications Combination with OTC medications Combination with alcohol

Combination with illicit drugs Prescription medications obtained illicitly Schedule I controlled substances Homicide (rare) Suicide (not so rare) Who Dies of Overdoses Involving Prescription Opioids? People without a prescription for those opioids Some who alter the route of administration Some who take them orally, with or without other drugs People with a prescription for those opioids Some who alter the route of administration

Some who take them orally, but with other drugs or otherwise not as directed Some who take them exactly as intended How many of the 16,000 deaths a year fall into each category? No one knows Important Patterns in Prescription Opioid Abuse We see a couple of important shifts as people become more experienced abusers of prescription opioids Early in the course: Family and friends are most common source of medication

(up to 70% or more) Swallowing is most common route of ingestion (more than 50%) Later in the course: Drug dealers and theft are more common sources for medication Inhalation (snorting, smoking) and injection are more common routes of ingestion FDA Actions: Abuse Deterrent Opioids (ADO) FDA has issued guidance for brand-name manufacturers

regarding requirements for abuse deterrent labeling Several extended release ADOs currently approved; more to follow soon Work is underway on short-acting ADOs as well Evidence so far suggests they are effective in reducing abuse that involves altering the form of the drug to permit inhalation or injection Evidence also suggests that this may shift some people toward heroin abuse (more on that later)

Six Types of Abuse Deterrent Technology *Physical/Chemical Barriers: Prevent alteration, or resist extraction using solvents *Agonist/Antagonist Combinations: If altered, antagonist is released, blocking effect of medication *Aversion: Combination with a product that produces unpleasant effect if medication is altered Delivery System: Drug release or delivery methods that

offer resistance to abuse Prodrug: Product must be metabolized in the GI tract to produce an active medication Combination of the above *Products currently approved for marketing FDA Actions: Abuse Deterrent Opioids (ADO) Things to remember: Abuse deterrent is a misnomer. Current ADOs may discourage or prevent crushing, cutting, melting, dissolving, extracting, or other forms of tampering, but they may not prevent chewing; none prevent swallowing These are not THE solution to the problem, but they ARE an incremental step forward

Because these are branded products, they will cost more than non-ADO generics It is a (small?) minority of people who alter their ER opioids; most likely dont even have a prescription ADOs: Policy Considerations Our position has been this: The decision whether or not to use an ADO should be made by the prescriber in consultation with the patient The decision should be informed by a thorough risk assessment Risk assessment includes the patient and people around the patient If an ADO is prescribed, the pharmacy should provide an ADOno auto-substitution to a non-ADO If a substitution either to or from and ADO is recommended by the

pharmacist, it should be only with the approval of the prescriber Those patients who do not require an ADO should not be forced to pay for one; we propose that any policy requiring use of an ADO also require insurance coverage equivalent to that for a similar nonADO A Final Word Medical professionals, especially those specializing in pain management, want to be part of the solution for prescription drug abuse In part, we need to better use some tools we already have In part, we need some additional tools to effectively treat chronic pain in ways that dont exacerbate prescription drug abuse

We are eager to work with policymakers to craft the complex solutions we need, for the good of all of their constituents and all of our patients Thank you for your attention

Recently Viewed Presentations

  • A mineral occurrence is any locality where a useful mineral ...

    A mineral occurrence is any locality where a useful mineral ...

    A mineral occurrence is any locality where a useful mineral or material is found. A mineral prospect is any occurrence that has been developed by underground or by above ground techniques, or by subsurface drilling to determine the extent of...
  • Chapter 5 Biological Explanations - Pearson

    Chapter 5 Biological Explanations - Pearson

    Positivistic Biological predisposition with environmental influences "born criminal" Environment and genetic > neurochemical > behaviour Another chapter done… Biological Explanations "Heredity is one of the reasons that parents with problems often have children with problems" J. Harris 98:294 Quick facts…
  • Science into Practice: How Do We Make it Matter

    Science into Practice: How Do We Make it Matter

    Science into Practice: How Do We Make It Matter? Evidence-Based Practices in Rural Environments John A. Morris, MSW Director, Human Services Practice Technical Assistance Collaborative, Inc. Professor and Director of Health Policy Studies, University of South Carolina School of Medicine
  • Chapter 1 Structure and Bonding - faculty.swosu.edu

    Chapter 1 Structure and Bonding - faculty.swosu.edu

    Expanded Shells Elements in the third or higher shells can have > 8 valence electrons Empty d-orbitals are used to hold excess electrons (s2p6d10 = 18e- max) Examples Resonance = ability to draw multiple Lewis structures for the same molecule...
  • Computer-Aided Verification of Electronic Circuits and Systems

    Computer-Aided Verification of Electronic Circuits and Systems

    v=R(i)i i=dq/dt=C(v)dv/dt Branch Constitutive Laws Inductors v=L(i)di/dt Mutual inductance V12=M12,34di34/dt Responses in Time Domain State Equation The solution to the above differential equation is the time domain response Where Exponential of a Matrix Properties of eA k! can be approximated...
  • Age & Gender Diversity - WKU

    Age & Gender Diversity - WKU

    AGE & GENDER DIVERSITY Carrie Guggenmos Spring 2012 This figure displays increases in employment by age and sex between 1977 - 2007. As you can see there are some large increases to take note of The number of individuals 65...
  • Looking Forward 2015: Florida State Report Conducted by

    Looking Forward 2015: Florida State Report Conducted by

    Changing market access regulations, permits, finance rules or taxation laws None of these 0.16 0.1 7.0000000000000007E-2 0.09 0.28999999999999998 0.44 Florida Members/Clients' members increasing their global or international activity Members/Clients' members adversely impacted by competition from other countries
  • Molienda en la Industria  Teora bsica  Tipos de

    Molienda en la Industria Teora bsica Tipos de

    ANTONIO VALENCIA E-mail: [email protected] Insert text with "Insert Header & Footer" GEA Pharma Systems Sheet3. Sheet2. Einfaches modell. Chart1. Particle size in μm. ideal. Gauss. r1. r2. reality raw. reality target. 18.00 101.22 102.56 Particle size in μm.